Details for Patent: 11,413,360
✉ Email this page to a colleague
Which drugs does patent 11,413,360 protect, and when does it expire?
Patent 11,413,360 protects POSLUMA and is included in one NDA.
This patent has twenty-nine patent family members in twenty countries.
Summary for Patent: 11,413,360
| Title: | Dual mode radiotracer and—therapeutics |
| Abstract: | The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation. |
| Inventor(s): | Alexander Josef Wurzer, Hans-Jürgen Wester, Matthias Johannes Eiber |
| Assignee: | Technische Universitaet Muenchen Klinikum Rechts Der Isar , Technische Universitaet Muenchen , Klinikum Rechts der Isar der Technischen Universitaet Muenchen |
| Application Number: | US16/634,759 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,413,360
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY | ⤷ Start Trial | |||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,413,360
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018308699 | ⤷ Start Trial | |||
| Australia | 2024200440 | ⤷ Start Trial | |||
| Brazil | 112020001785 | ⤷ Start Trial | |||
| Canada | 3071315 | ⤷ Start Trial | |||
| China | 111132700 | ⤷ Start Trial | |||
| Denmark | 3658194 | ⤷ Start Trial | |||
| Eurasian Patent Organization | 202090370 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
